BTF granted US patent for 'Bioballs'

By Renate Krelle
Thursday, 23 September, 2004

Private Sydney-based biotech BTF has been granted a US patent for its BioBall quality-control product.

The patent protects its BioBall technology, which uses a flow cytometer to count out precisely 30 viable bacteria. The bacteria are freeze dried in a drop of nutrient fluid as a 'Bioball' pellet.

The pellets can be reconstituted and used as a control, eliminating the need for labs to perform routine serial dilutions.

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...

Content from other channels on our network

Innovating chemical dosing & dilution in aged care

A shift in clinical practice: optimal antibiotics for golden staph bloodstream infections

The rise of non-clinical, community-led safe spaces: how lived experience is reshaping suicide prevention

Mandatory VR violence training for nursing students

National virtual care standards on the way

GWW to provide recycled water for a Victorian data centre

Valves, data centres and the invisible infrastructure of Australian industry

NVIDIA technology aims to give factories an AI brain

New Energy Transport secures funding to accelerate electric road freight

DroneShield marks global manufacturing milestone in Europe

Vacuum Cooling. The fix to your cooling bottleneck.

SAVE FOOD Initiative award winners from interpack

WA dog food manufacturer seals SE Asia export deal

Food safety recalls in NZ: the 2025 report

From raw to rare sugar: low-cal sweetener under development